ArticleOncotarget2018

Conception, synthesis, and characterization of a rofecoxib-combretastatin hybrid drug with potent cyclooxygenase-2 (COX-2) inhibiting and microtubule disrupting activities in colon cancer cell culture and xenograft models.

Surendra R Punganuru et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.